Billable / Specific Code
ICD-10-CM G73.1 is the diagnosis code for Lambert-Eaton syndrome in neoplastic disease. This code falls under the section "Diseases of myoneural junction and muscle" within Chapter 6 — Diseases of the nervous system (G00-G99). It is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Medical coders and healthcare providers use this code to document and classify diagnoses in electronic health records, insurance claims, and clinical databases.
The following conditions should never be coded at the same time as G73.1. They are mutually exclusive:
Understanding where G73.1 sits in the ICD-10-CM classification helps ensure proper coding:
Yes, G73.1 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
G73.1 is the ICD-10-CM diagnosis code for "Lambert-Eaton syndrome in neoplastic disease". It is used by healthcare providers to classify and document this condition in medical records and insurance claims.
The parent code of G73.1 is G73 ("Disorders of myoneural junction and muscle in diseases classified elsewhere"). G73.1 provides a more specific classification within this category.
G73.1 is located in Section G70-G73 — "Diseases of myoneural junction and muscle" within Chapter 6 of the ICD-10-CM Tabular List.
Use G73.1 when the patients documented diagnosis matches "Lambert-Eaton syndrome in neoplastic disease" and the clinical documentation supports this level of specificity. Always verify with the latest ICD-10-CM guidelines and payer requirements.
The ICD-10-CM code for Lambert-Eaton syndrome in neoplastic disease is G73.1.
Yes, G73.1 can be used as a primary diagnosis code since it is billable and specific.
G73.1 is in Chapter 6 of the ICD-10-CM Tabular List.
Type 1 Excludes for G73.1 include: Lambert-Eaton syndrome not associated with neoplasm (G70.80-G70.81).
Yes, G73.1 is a valid ICD-10-CM code for the 2026 fiscal year, subject to official CMS updates.